T1	Intervention 494 505	ebrotidine,
T2	Intervention 742 959	The patients were assigned to 5 groups: placebo, 200 mg, 400 mg, 600 mg and 800 mg of ebrotidine once daily. Controls were performed at baseline and every two weeks at four follow-up visits unless ulcer healed before.
T3	Intervention 1071 1139	Vital signs and blood/ urine analysis were used to establish safety.